Adcentrx Therapeutics Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ADRX-0706, a groundbreaking Antibody-Drug Conjugate (ADC) that targets Nectin-4 to treat advanced solid tumors. This marks the first time that Adcentrx's ADC platform has been granted FDA clearance, signaling a major milestone for the company. The Phase 1a/1b clinical trial for ADRX-0706 is scheduled to commence in the second half of 2023.
Nectin-4 is an ideal target for ADCs as it is highly expressed in various types of solid tumors while having limited expression in normal tissues. By specifically targeting Nectin-4 with ADRX-0706, the treatment can effectively combat cancer cells with reduced toxicity compared to existing therapeutic approaches.
The upcoming Phase 1a/1b clinical trial will be an open-label, multicenter study that aims to enroll patients with specific advanced solid tumors.